Q1-FY26 · Prabhat Agarwal
We have started the new financial year on a strong note with Q1 revenues growing 28% year-on-year as against the IPM growth of 9%.
ENTERO / language trends
Read confidence between the lines.
Entero Healthcare Solutions · tone and specificity signals across the available quarters.
Research layer active
Language signals
What changed in management language.
tracked
Q1-FY26 · Prabhat Agarwal
Acquisitions will remain an important lever for growth but our approach will continue to be disciplined and value effective.
Q1-FY26 · Prabhat Agarwal
Our pan India technology-led and category neutral platform is difficult to replicate. This positions us uniquely to capture outsized share gains as the market consolidates.
Q4-FY26 · Prabhat Agarwal
We have delivered on each of these parameters: revenue growth of 30% year-on-year on like-for-like basis, EBITDA margin of 4% for the full year, and operating cash flow.
Q4-FY26 · Prabhat Agarwal
We aim for consolidated revenue growth of 23% year-on-year excluding any new acquisitions with 5% EBITDA margins.
Q4-FY26 · Prabhat Agarwal
The reason why medtech margins are higher than pharma is because we play a more commercial role in those contracts where we are also responsible for generating demand and sales.